

 Mission of AABC

The mission of the Alzheimer's Association[®] Business Consortium (AABC) is to advance Alzheimer's disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer's research and the goals of its member organizations. They provide leadership and direction to the groups' areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new member organizations who are aligned in their commitment to research and innovation. To express interest in joining, please email co-chairs Dr. Alexis Moscoso (alexis@zroimaging.com) or Dr. Paul Slowey (pds@4saliva.com), or Dr. Christopher Weber (cweber@alz.org), facilitator.

 Welcome to our New Co-Chair

Congratulations to Dr. Alexis Moscoso, who was elected as the new AABC co-chair for a two-year term. Dr. Moscoso is the Chief Science Officer at ZRO Imaging. We are delighted to have him serving in this role. The Alzheimer's Association extends its gratitude to outgoing co-chair Dr. Theresa Devins for her service to AABC. Under her leadership, AABC has grown in membership and hosted events that have advanced our mission. We look forward to working with the two co-chairs, Dr. Moscoso and Dr. Slowey, in the upcoming year, and would like to thank everyone for their continued participation.

 Welcome New Members

AABC is growing! Welcome to:

- » **Aquinnah Pharmaceuticals Inc.** is led by Glenn Larsen (CEO) and Ben Wolozin (CSO). Aquinnah is a biotechnology company that develops small molecules to treat Alzheimer's disease and related dementias. Aquinnah's lead compound, AQV-8741, reduces toxic tau oligomers by dispersing stress granules and muting the chronic stress response. AQV-8741 is an orally bio-available, brain penetrant small molecule that is safe, effective in vivo, effective in human iPSC models, and is poised for an IND application with a subsequent Phase I clinical trial. Aquinnah's program is supported by NIH, Alzheimer's association (PTC and TPEP x 2), the Rainwater Foundation (TPEP x 2) and Alzheimer's Drug Discovery Foundation. Aquinnah looks forward to its interactions with AABC as we all seek to develop the next generation of treatments for Alzheimer's disease.
- » **AtendaCare** is a conversational AI companion designed to support family dementia caregivers while helping clinicians see what happens at home between visits. Through simple, natural conversations, "Atenda" helps caregivers document observations, recognize meaningful changes, and feel less alone in the day-to-day challenges of dementia care. With the caregiver's permission, those conversations are transformed into concise clinical summaries that give physicians a clearer picture of what's happening at home, between appointments.
Our mission is simple: support every caregiver, and ensure no clinician has to make decisions without seeing what happened at home.
- » **Elixiron** Immunotherapeutics and its neuroscience-focused subsidiary, NeuroVantix Therapeutics, are clinical-stage biotechnology companies dedicated to developing novel precision immunotherapies for immune-mediated and neurodegenerative diseases, including Alzheimer's disease. Their founder and CEO, Dr. Hung-Kai Kevin Chen, is a two-time recipient of the Alzheimer's Association Part the Cloud award, which has supported and accelerated the clinical development of enrupatinib (EI-1071). Enrupatinib is a brain-penetrant CSF-1R inhibitor designed to modulate microglia-mediated neuroinflammation. In an ongoing Phase II clinical trial in patients with Alzheimer's disease, enrupatinib has generated encouraging preliminary evidence of reduced neuroinflammation, supporting its continued development as a potential disease-modifying therapy. As a new member of the AABC, Elixiron looks forward to engaging with the community and contributing to collective efforts to accelerate therapeutic innovation for people living with Alzheimer's disease.

- » **PorchLink** is an AI-powered digital phenotyping platform designed for older adults aging independently and the family caregivers who support them. By analyzing passive signals from everyday devices already present in the home, PorchLink helps identify meaningful changes in daily routines and builds a deeper understanding of individual behavioral patterns over time. Our goal is to provide earlier awareness of potential changes in well-being while preserving privacy, independence, and dignity. Because every journey starts with a signal.
- » **Mentalness** is a U.S.-based neurotechnology and scientific AI company developing non-invasive, personalized approaches to support neuroplasticity, cognitive health, and healthy aging. Our proprietary Synchronized Multisensory Modulation methodology integrates coordinated visual, auditory, tactile, immersive, olfactory, and radiofrequency stimulation with physiological and neurophysiological measurement. Building on more than two decades of scientific research and over 300 peer-reviewed publications from its academic and clinical team, Mentalness is developing adaptive, data-driven interventions for cognitive decline, Alzheimer's disease, stress-related disorders, attention, and neurological rehabilitation. The company is currently advancing its Mentalness NEXUS platform, designed to combine multisensory stimulation, wearable technologies, brain-state modeling, and closed-loop artificial intelligence to enable the next generation of personalized digital neurotherapeutics.
- » **SiteRx** is a next-generation life sciences technology company that is democratizing access to clinical research via the largest CNS-focused real world data network in the United States. SiteRx works with pharmaceutical and biotechnology companies to help them leverage real world data to optimize their R&D lifecycle. SiteRx is headquartered in New York, NY, with offices in Orlando, FL and London, UK.
- » **Switch Therapeutics**, located in South San Francisco, California, is developing precision genetic medicines for central nervous system disorders such as Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, and other neurodegenerative diseases with high unmet need. The company's proprietary conditionally activated siRNA (CASI) platform combines advantageous properties of single- and double-stranded RNA in a single molecule, enabling self-delivery, cellular uptake, with potent, durable knockdown of target mRNA transcripts. By targeting mRNA in specific cell types and cell states, the CASI platform has the potential to transform the treatment of devastating diseases. Building on this platform, Switch is advancing programs targeting MAPT, APOE, and C1q. For additional information about the platform or specific programs, please contact Dr. Anindya Bhattacharya, VP, Head of Neuroscience, at anindya@switchthera.com, or Dr. Craig Blanchette, CSO, at craig@switchthera.com.



AABC News

AriBio Completes Treatment Phase of Global Phase 3 POLARIS-AD Trial

AriBio Co., Ltd. announced the completion of the treatment phase of POLARIS-AD (NCT05531526), its global Phase 3 registration trial of AR1001, a disease-modifying investigational once-daily oral therapy for early Alzheimer's disease (AD). POLARIS-AD enrolled 1,535 participants across approximately 230 sites in 13 countries, including the United States, Canada, Europe, the United Kingdom, South Korea and China. A total of 1,348 participants completed the 52-week treatment period. The study has advanced to data cleaning, validation, database lock, and pre-specified statistical analyses. Topline efficacy and safety results are expected in Q4 2026, with detailed results planned for presentation at CTAD 2026 in Boston, November 16–19. Of eligible participants, 95.5% elected to continue in the optional long-term extension treatment phase — 1,288 participants — which is scheduled to conclude in mid-2027.

Over 62% of the participants in POLARIS-AD were enrolled based on CSF Aβ ratio, making the trial one of the largest sources for matched plasma and CSF samples for early AD patients. Under a strategic partnership with Fujirebio Diagnostics, Inc., AriBio provided clinical samples and data from the ongoing POLARIS-AD trial for Fujirebio to validate Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in vitro diagnostic test, which was subsequently cleared by FDA as the first blood-based biomarker test to aid in the diagnosis of Alzheimer's disease. POLARIS-AD was the largest sample source supporting the FDA submission.

AriBio is committed to developing life-changing therapies and advancing the understanding of AD together through its growing network of partnerships.

Part the Cloud Translational (PTC) Research for Alzheimer's Disease Program: Phase 1 and Phase 2 Clinical Studies

The Alzheimer's Association is pleased to announce the next offering of the Part the Cloud Translational Research Funding initiative to increase the research efforts in early-stage human clinical trials (Phase 1 and 2) evaluating novel or repurposed potential medications directed towards Alzheimer's disease and related dementias internationally. In some scenarios, a phase 3 program would also be eligible.

Key dates and deadlines:

Letter of Intent due: Oct. 20, 2026 – 5 p.m. ET (Oct. 22 for ISTAART members)

Full application due: Dec. 15, 2026 – 5 p.m. ET (Dec. 17 for ISTAART members)

Award notifications: by March 15, 2027

More information can be found here.

https://www.alz.org/research/for_researchers/grants/types-of-grants/part-the-cloud-translational-research



Upcoming Conferences

AAIC® Advancements: Reducing Disparities in Brain Health

Registration is open for our newest meeting taking place Oct. 30-31, in Charlotte, NC and online. AAIC Advancements: Reducing Disparities in Brain Health will convene leaders from academia, community organizations, government and philanthropy to advance brain health for all. By bringing together speakers and participants from diverse disciplines, sectors and career stages, this meeting is designed to move the field beyond understanding disparities and toward generating real-world solutions that improve brain health across communities and settings.

Register today to join us in Charlotte or online.

<https://www.alz.org/reducing-disparities-brain-health>



Social Media

Follow our [LinkedIn](#) page! We look forward to using the page to foster partnerships and communications.



Spread the Word

To help us grow AABC, please continue to introduce new members and companies to our group. We also welcome ideas or events for this newsletter so we can better serve you. Please send your suggestions to Ashley Hansen at (ahansen@alz.org).